Independent
Tenure on this board
12.8 yrs
Also a director at
908 Devices Inc (MASS)
Meeting calendar
TWST · Annual meeting · Thursday, February 5, 2026
Twist Bioscience Corp
3 nominees · 3 ballot items.
Elect three Class II directors; advisory vote to approve named executive officer compensation (Say-on-Pay); ratify Ernst & Young LLP as independent registered public accounting firm for fiscal year ending September 30, 2026.
Market cap
$5.8B
1Y TSR
+155.2%
Board grade
B-
Record date
Dec 26, 2025
Filing
DEF 14A
Meeting concluded · Feb 5, 2026
Follow how the vote landed and what changed on Twist Bioscience Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of three Class II directors
ManagementBoard: FORElect three Class II directors (Keith Crandell, Jan Johannessen, Trynka Shineman Blake) to serve three-year terms until the 2029 annual meeting.
- 2
Non-binding, advisory vote to approve the compensation of our Named Executive Officers (Say-on-Pay
ManagementBoard: FORAdvisory vote to approve the compensation of the company’s named executive officers as disclosed in the proxy statement.
- 3
Ratification of appointment of independent registered public accounting firm (Ernst & Young LLP
ManagementBoard: FORRatify the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal year ending September 30, 2026.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
7.8 yrs
Trynka Shineman Blake
Independent
Tenure on this board
New nominee
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Artisan Partners Limited Partnership | 10.2% | 6,367,777 | $303M |
| 2 | ARK Investment Management LLC | 10.2% | 6,342,733 | $301M |
| 3 | EdgePoint Investment Group Inc. | 8.6% | 5,382,521 | $256M |
| 4 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 8.5% | 5,269,718 | $250M |
| 5 | STATE STREET CORP | 5.9% | 3,670,682 | $174M |
| 6 | BlackRock, Inc. | 4.4% | 2,767,058 | $131M |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.3% | 2,649,101 | $126M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 2,639,044 | $125M |
| 9 | Invesco Ltd. | 3.3% | 2,033,802 | $97M |
| 10 | BlackRock, Inc. | 3.1% | 1,908,696 | $91M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Twist Bioscience Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.7B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$3.9B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.5B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the Twist Bioscience Corp 2026 annual meeting?
- Twist Bioscience Corp (TWST) holds its 2026 annual shareholder meeting on Thursday, February 5, 2026.
- What is the record date for the Twist Bioscience Corp 2026 meeting?
- The record date for the Twist Bioscience Corp 2026 meeting is Friday, December 26, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Twist Bioscience Corp's 2026 meeting?
- The board is presenting 3 director nominees at the Twist Bioscience Corp 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Twist Bioscience Corp 2026 meeting?
- Shareholders will vote on 3 proposals at the Twist Bioscience Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.